Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding - 10/12/14
Doi : 10.1016/j.ahj.2014.09.007
John A. Cairns, MD, FRCPC a, ⁎ 
, Jeffrey I. Weitz, MD, FRCPC b
, Jeffrey I. Weitz, MD, FRCPC b a Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
b Department of Medicine, McMaster University, and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
⁎Reprint requests: John A. Cairns, MD, FRCPC, UBC Division of Cardiology, Rm 9113, GLD Health Care Centre, 2775 Laurel St, Vancouver, BC, Canada V5Z 1M9.
Il testo completo di questo articolo è disponibile in PDF.
| Stuart J. Connolly, MD, served as guest editor for this article. |
|
| Conflicts of interest: Dr Cairns has served as a consultant and has received honoraria from Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, and Pfizer. He chairs the DSMB of the ARTESIA trial of apixaban vs aspirin among patients with subclinical atrial fibrillation, sponsored in part by Bristol-Myers Squibb, and Pfizer, and he is vice chair of the DSMB of the COMPASS trial of rivaroxaban vs aspirin in patients at risk of vascular events, sponsored by Bayer. Dr Weitz has served as a consultant and has received honoraria from Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo. He is co-chair of the ongoing EINSTEIN-Choice trial and a member of the Steering Committee of the MARINER trial, both of which are with rivaroxaban. |
© 2014
Elsevier Inc. Tutti i diritti riservati.
Vol 169 - N° 1
P. 1-3 - Gennaio 2015 Ritorno al numero
Articolo precedente
- Information for Readers
- Anger and mental stress–induced myocardial ischemia: Mechanisms and clinical implications
- Redford B. Williams
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?